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a b s t r a c t
Background: Extramedullary plasmacytomas (EMP) are rare plasma cell tumors that arise
outside the bone marrow. They are most often located in the head and neck region, but may
also occur in the other locations. The lower gastrointestinal EMP represents less than 5% of
all cases, and location in the anal canal is exceedingly rare.
Aim: We present an exceedingly rare case of anal canal plasmacytoma, aiming to achieve a
better understanding of this rare entity.
Methods: We report a case of a 61-year-old man with a bulky mass in the anal canal. The
lesion measured about 6 cm and invaded in all layers of the anal canal wall. The biopsy
was performed and revealed a round and plasmocitoid cell population with a solid growth
pattern and necrosis. The tumoral cells have express CD79a and CD138 with lambda chains.
There was no evidence of disease in other locations and these features were consistent
with the diagnosis of an extra-osseous plasmacytoma. The patient was submitted to con-
formal radiotherapy 50.4Gy total dose, 1.8Gy per fraction. After 24 months, the patient is
asymptomatic and the lesion has completely disappeared.
Conclusions: EMP accounts for approximately 3% of plasma cell malignancies. The medianage is about 60 years, and the majority of patients are male. The treatment of choice for
extramedullary plasmacytoma is radiation therapy in a dosage of about 50Gy. Patients
should be followed-up for life with repeated bone marrow aspiration and protein studies
to detect the development of multiple myeloma.
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1. Background
Solitary plasmacytomas (SP), a monoclonal proliferation of
plasma cells without evidence of signiﬁcant bone-marrow
plasma-cell inﬁltration, is comprised of two main groups:
solitary plasmacytoma of the bone (SPB) and extramedullary
plasmocytoma (EMP). SP is a rare disease, and accounts
for about 10% of plasma cells tumors.1–3 The clini-
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cal presentation of the former generally includes bone
involvement, with pain, neurological deﬁcit and, some-
times, pathological fractures. The latter often presents as a
mass which becomes symptomatic if compresses adjacent
structures.EMPs are most often located in the head and neck region,
mainly in the upper aerodigestive tract, but may also occur
in the gastrointestinal tract, urinary bladder, central nervous
system, thyroid, breast, testes, parotid gland, lymph nodes,
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.































Fig. 2 – Axial CT.
Fig. 3 – Axial CT.Fig. 1 – Axial CT.
nd skin. The lower gastrointestinal EMP represents less than
% of all cases.
We report an exceedingly rare case of anal canal plasma-
ytoma, aiming to achieve a better understanding of this rare
ntity.
. Case report
61-year-old white man presented with a 4-month history of
bdominal discomfort, tenesmus and perineal pain. On phys-
cal examination, he was in a good general status (IK 90%, PS
). The digital rectal examination (DRE) revealed an imping-
ng mass, of about 4 cm, hard consistency, at 2 cm of the anal
argin, in the left posterior margin, without any palpable
odes. The blood testing showedhaemoglobin 11.9 g/dL,white
lood cells 5.73×109/L,  2microglobulinwas slightly elevated
3.13mg/L; Ref. 0.8–1.8mg/L), and the protein electrophoresis
evealed a slender elevation of the IgG. The pelvic CT revealed
bulky mass in the anal canal of about 6 cm that invaded all
ayers (Figs. 1–3). The biopsy was performed and histological
xamination identiﬁed a round and plasmocitoid cell popula-
ion with solid growth pattern and necrosis. The tumoral cells
xpressed CD79a and CD138 with lambda light chains (Fig. 4).
There was no evidence of disease in other locations and
hese features were consistent with the diagnosis of an
xtramedullary plasmocyoma (EMP) according to Interna-
ional Myeloma Working Group (IMWG).4
The patient was referred to our department and submit-
ed to conformal 3D external radiotherapy (RT) directed to
he lesion with a total dose of 50.4Gy, 1.8Gy/F, 5F/week. The
rradiated PTV1 included the tumor identiﬁed in the clinical
2xam and planning TC (GTV ) and a margin for subclinical
isease (CTV3) and for variations and uncertainties (PTV). Dur-
ng the treatment, the patient complained about dysuria and
ccasional hematuria, which were treated with nonsteroidal
1 PTV – planning target volume.
2 GTV – gross tumor volume.
3 CTV – clinical target volume.
Fig. 4 – Photomicrograph.
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Fig. 5 – Axial MRI.
years after RT.Fig. 6 – Coronal MRI.
anti-inﬂammatory drug (NSAIDs) and completely resolved at
the end of RT. He alsomentioned resolution of the initial com-
plaints that had led to the diagnosis.
Six months after RT, the patient was asymptomatic and
the lesion was markedly reduced (about 70%). One year later
the mass completely disappeared, and only ﬁbrotic changes
were identiﬁed on pelvic MRI (Figs. 5–7). There was no bone
marrow inﬁltration or other multiple myeloma (MM) features.
The patientmaintained the response at last followup, twenty-
four months after treatment.
3. Discussion
Extramedullary plasmocyoma (EMP) is characterized by
the presence of a monoclonal plasma cell tumor at an
extramedullary site with no evidence of MM. Some patients
may have a smallM-protein in the serumor urine, which often
disappears after treatment.4,5The lower gastro-intestinal tract is an uncommon site for
EMPs, since they are usually located in the stomach or small
bowel.Fig. 7 – Sagittal MRI.
For diagnosis, a positive tissue biopsy is required. MRI of
pelvis is recommended to better characterize the lesion and
subsequently for RT planning.
Multiple lesions should be excluded in order to select
patients eligible for radical RT.6,7 Positron emission tomog-
raphy (PET) with 18F-ﬂuoro-deoxyglicose (FDG) is becoming
more relevant in diagnosis and staging of many tumors,
including lymphoma, and – aswhole body imaging exam – can
reveal new sites of disease otherwise ignored by other recom-
mended imaging modalities, such as bone scan, TC or MRI.
PET has been proven to be useful in diagnosis and assessing
the response to RT in SP.7,8 It may also be very useful in RT
planning, as images can be imported into treatment planning
systems (TPS).7
Surgery and RT may be used for EMP treatment.9–12 If the
patient has been performed a complete resection during the
diagnosis evaluation, adjuvant RT is indicated only if there is
a suspicion of residual disease. Otherwise, IFRT is the treat-
ment of choice in a great majority of cases, with a high cure
rates. Currently, there is no conclusive data published on the
optimal radiation dose for SP. Doses varying from 30 to 60Gy
are described, but most centers use ≥50Gy.8,13
Many authors agree that age is a prognostic factor for pro-
gression to MM, while others do not. As MM is more common
in the elderly, many patients diagnosed with EMP hypotheti-
cally harbor subclinical disease which has not been detected.
Persistence of M-protein after RT may predict subsequent
systemic failure.3,4,8 Tumor size is relevant for local con-
trol. Authors report better outcome in lesions <5 cm.3 Some
other factors, such as local invasiveness, proliferation rate
andmorphologic grade, usually barely documented,may have
an effect on the outcome.8 Although our patient presented a
tumor bigger than 5 cm, M-protein was absent after RT.
In our case, after radical treatment with RT, there was no
evidence of disease and our patient remains disease free twoThe frequencyof progressionofMMtoSPafter RTdescribed
in the literature suggests that, at least in some cases, the stag-















plasmacytoma: Outcome and prognostic factors following
radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:1063–7.reports of practical oncology an
se of PET may improve patients’ staging and more patients
ould be diagnosed with MM instead of SP, which could opti-
ize treatment.
Theoretically, chemotherapy might have a role in eradicat-
ng subclinical disease and enhancing local control.8
As it is not yet possible to predict which patients will
rogress to MM, we recommend that all patients should be
ollowed-up for life with periodical lab exams and imaging.
. Conclusion
his paper is, to our knowledge, one of few reports in the lit-
rature of EMP of the anal canal. Further reports of new cases
an help establish optimal treatment guidelines.
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